Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer

Codony-Servat, J. ; Cuatrecasas, M. ; Asensio, E. ; Montironi, C. ; Martinez-Cardus, A. ; Marin-Aguilera, M. ; Horndler, C. ; Martinez-Balibrea, E. ; Rubini, M. ; Jares, P. ; Reig, O. ; Victoria, I. ; Gaba, L. ; Martin-Richard, M. ; Alonso, V. ; Escudero, P. ; Fernandez-Martos, C. ; Feliu, J. ; Mendez, J.C. ; Mendez, M. ; Gallego, J. ; Salud, A. ; Rojo, F. ; Castells, A. ; Prat, A. ; Rosell, R. ; Garcia-Albeniz, X. ; Camps, J. ; Maurel, J.
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer
Resumen: Background: Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving. Methods: We analysed time to progression, overall survival, and the mutational status of RAS, BRAF and nuclear p-IGF-1R expression by immunohistochemistry, in 470 metastatic CRC patients. The effect of IGF-1R activation and distribution was also assessed using cellular models of CRC and RNAi for functional validation. Results: Nuclear IGF-1R increased in metastatic tumours compared to paired untreated primary tumours, and significantly correlated with poor overall survival in mCRC patients. In vitro, chemo-resistant cell lines presented significantly higher levels of IGF-1R expression within the nuclear compartment, and PIAS3, a protein implicated also in the sumoylation process of intranuclear proteins, contributed to IGF-1R nuclear sequestration, highlighting the essential role of PIAS3 in this process. Intriguingly, we observed that ganitumab, an IGF-1R blocking-antibody used in several clinical trials, and dasatinib, an SRC inhibitor, increased the nuclear localisation of IGF-1R. Conclusions: Our study demonstrates that IGF-1R nuclear location might lead to chemotherapy and targeted agent resistance.
Idioma: Inglés
DOI: 10.1038/bjc.2017.279
Año: 2017
Publicado en: BRITISH JOURNAL OF CANCER 117, 12 (2017), 1777-1786
ISSN: 0007-0920

Factor impacto JCR: 5.922 (2017)
Categ. JCR: ONCOLOGY rank: 38 / 222 = 0.171 (2017) - Q1 - T1
Factor impacto SCIMAGO: 2.89 - Oncology (Q1) - Cancer Research (Q1)

Tipo y forma: Article (Published version)

Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material.

Exportado de SIDERAL (2019-07-09-12:04:54)

Este artículo se encuentra en las siguientes colecciones:

 Record created 2018-11-07, last modified 2019-07-09

Versión publicada:
Rate this document:

Rate this document:
(Not yet reviewed)